Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

    Research grant utilizing PLCO bioresources for advancing cancer etiology and early detection biomarkers through biochemical and genetic analyses.

    Browse similar grants
    Cancer Research Grants 2026
    OverviewSimilar Grants
    OverviewSimilar Grants

    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

    Explore existing data to uncover cancer risk insights, seeking to understand outcomes like survival and treatment response.

    HHS-NIH11Due Nov 5, 2026· 10d$1,750,000

    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

    This grant supports researchers in analyzing existing data to understand cancer risk and related outcomes, aiming to address key scientific questions in cancer research.

    HHS-NIH11Due Nov 16, 2026· 21d$275,000

    Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

    This grant funds multidisciplinary teams to develop and validate biomarkers and imaging tools for early detection of pancreatic cancer and its precursors, focusing on high-risk individuals and collaborative research.

    HHS-NIH11Due Nov 5, 2029$600,000

    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

    This grant funds early-stage, highly innovative technology development for improving analysis and handling of biospecimens in basic or clinical cancer research, focusing on proof-of-concept studies.

    HHS-NIH11Due Nov 10, 2026· 15d$150,000

    Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)

    This grant funds research on causes, biological mechanisms, and early detection of non-hereditary early-onset cancers (ages 18-49) to inform prevention and control strategies.

    HHS-NIH11Due Oct 11, 2029